Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

By M. aan het Rot, K. Collins, J. Murrough, A. M. Perez, D. Reich, Dennis S. Charney, S. Mathew. Biological Psychiatry, 2010

670 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial (2013, neutral): “Additional infusions of ketamine have recently been explored to prolong the antidepressant response (22, 40), although controlled data testing this strategy are not currently available.”
Immune System to Brain Signaling: Neuropsychopharmacological Implications (2011, background): “N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript resistant depression (aan het Rot et al., 2010).”
Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications (2013, background): “…receptor antagonists, such as the NMDA antagonist, ketamine, have potent antidepressant effects especially in treatment resistant depressed patients (Price et al., 2009, aan het Rot et al., 2010), who, as mentioned previously (section 2.1), have been shown to exhibit increased inflammation.”
Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial (2017, methodology): “The study consistedof 4phases: (1) screening; (2) doubleblind treatment (days 1-15), composed of two 1-week periods (period 1, period2); (3) optional open-label treatment (days 1574)with taperingof intranasal dosing frequency; and (4) posttreatment follow-up (8 weeks).”